(Q33401684)

26 July 2017

Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial (English)

1 reference

26 July 2017

phase I clinical trial

0 references

phase II clinical trial

0 references

1 reference

Fernando Cabanillas

11

0 references

Luis E. Fayad

2

Luis Fayad

0 references

Michelle A Fanale

9

Michelle Fanale

1 reference

26 July 2017

6

Sattva S Neelapu

1 reference

26 July 2017

12

Nathan Fowler

1 reference

26 July 2017

17

Larry Kwak

1 reference

26 July 2017

Fredrick B Hagemeister

5

Fredrick Hagemeister

1 reference

26 July 2017

8

Peter McLaughlin

1 reference

26 July 2017

27

Jorge Romaguera

1 reference

26 July 2017

7

Felipe Samaniego

1 reference

26 July 2017

10

Anas Younes

1 reference

26 July 2017

21

Kimberly Hartig

1 reference

María Auxiliadora Badillo-Viloria

26 July 2017

19

Maria Badillo

1 reference

26 July 2017

15

Ken H Young

1 reference

26 July 2017

16

Richard Champlin

1 reference

26 July 2017

Nicolaus A Wagner-Bartak

3

Nicolaus Wagner-Bartak

1 reference

26 July 2017

Michael Wang

1

1 reference

26 July 2017

Liang Zhang

4

1 reference

26 July 2017

Kate J Newberry

13

1 reference

26 July 2017

Luhong Sun

14

1 reference

26 July 2017

Lei Feng

18

1 reference

26 July 2017

Maria Bejarano

20

1 reference

26 July 2017

Wendy Chen

22

1 reference

26 July 2017

Yiming Chen

23

1 reference

26 July 2017

Catriona Byrne

24

1 reference

26 July 2017

Neda Bell

25

1 reference

26 July 2017

Jerome Zeldis

26

1 reference

26 July 2017

6 June 2012

1 reference

Lancet Oncology Commission

26 July 2017

1 reference

26 July 2017

13

1 reference

26 July 2017

7

1 reference

26 July 2017

716-723

1 reference

Pathogenesis of mantle-cell lymphoma: all oncogenic roads lead to dysregulation of cell cycle and DNA damage response pathways

26 July 2017

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970200-0

7 January 2021

Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970200-0

7 January 2021

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970200-0

1 reference

7 January 2021

High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970200-0

7 January 2021

Phase 2 trial of rituximab plus hyper-CVAD alternating with rituximab plus methotrexate-cytarabine for relapsed or refractory aggressive mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970200-0

7 January 2021

Effect of single-agent rituximab given at the standard schedule or as prolonged treatment in patients with mantle cell lymphoma: a study of the Swiss Group for Clinical Cancer Research (SAKK).

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970200-0

7 January 2021

European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970200-0

7 January 2021

Regression of refractory intraocular large B-cell lymphoma with lenalidomide monotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970200-0

7 January 2021

A review of the history, properties, and use of the immunomodulatory compound lenalidomide.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970200-0

7 January 2021

Synergistic antitumor effects of lenalidomide and rituximab on mantle cell lymphoma in vitro and in vivo

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970200-0

7 January 2021

lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970200-0

7 January 2021

Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970200-0

7 January 2021

Optimal two-stage designs for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970200-0

7 January 2021

Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970200-0

7 January 2021

Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970200-0

7 January 2021

Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970200-0

7 January 2021

Bortezomib in patients with relapsed or refractory mantle cell lymphoma: updated time-to-event analyses of the multicenter phase 2 PINNACLE study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970200-0

7 January 2021

Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970200-0

7 January 2021

An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970200-0

7 January 2021

Lenalidomide oral monotherapy produces a high response rate in patients with relapsed or refractory mantle cell lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970200-0

7 January 2021

Phase II multicenter study of bendamustine plus rituximab in patients with relapsed indolent B-cell and mantle cell non-Hodgkin's lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970200-0

7 January 2021

Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2812%2970200-0

7 January 2021

10.1016/S1470-2045(12)70200-0

Identifiers

DOI

1 reference

26 July 2017

1 reference